Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

Summary

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.

Timeline

Start

2010-10

Primary completion

2013-12

Completion

2013-12

Outcome

Met primary endpoint

release “The Phase IIb RA study showed that CF101 met all primary efficacy endpoints” canfite.com ↗

Drugs

Indications